Transmedics Group Stock

Transmedics Group Equity

The The Equity of Transmedics Group (TMDX) as of Aug 7, 2026 is 473.10 M USD. In the previous year, The Equity was 228.60 M USD — a change of 106.95% (higher).

Equity

473.10 MUSD

YoY

106.95%

Last updated:

In 2026, Transmedics Group's equity was 473.10 M USD, a 106.95% increase from the 228.60 M USD equity in the previous year.

Access this data via the Eulerpool API

Transmedics Group Stock analysis

What does Transmedics Group do? Transmedics Group Inc is a company dedicated to the development and manufacturing of medical devices for organ transplantation. The company was founded in 1998 and is headquartered in Andover, Massachusetts, USA. Transmedics' business model is based on offering a unique and innovative technology for organ preservation during transport from donor to recipient. The patented Organ Care System (OCS) platform includes a range of state-of-the-art medical devices specifically designed for organ transport. Transmedics' Organ Care System includes three main devices: OCS Heart, OCS Lung, and OCS Liver. Each device is tailored for organ preparation and transport, providing individualized support based on the specific requirements of each organ and different transfer protocols. The OCS technology uses hypothermic (cold) perfusion to preserve the organ during transport. By continuously monitoring and supporting the organ's physiological functions, the OCS system can improve the survival rate of donor organs while reducing the time spent outside the body. Transmedics also offers comprehensive services, including the availability of OCS devices and qualified personnel to provide support throughout the transplantation process. Transmedics' customers include leading transplant centers and hospitals worldwide. The company works closely with these customers to ensure that its OCS devices meet the specific requirements of each transplantation program and help them achieve more successful transplantations. Transmedics' history is marked by a passion for improving transplantation medicine and saving lives through the provision of advanced technologies and solutions. The company has made significant progress in recent years and has experienced strong growth in all areas. Transmedics has also received a number of awards and recognition for its commitment to improving transplantation medicine. For example, in 2020, the company received the Red Herring Top 100 Global Award and was recognized for the seventh consecutive year as one of the fastest-growing companies by Deloitte. Overall, Transmedics is a leading provider of innovative medical devices for transplantation medicine. Through its organic technology and comprehensive service, the company supports transplant centers and hospitals worldwide in performing more successful transplantations and saving patients' lives. Transmedics Group is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Transmedics Group's Equity

Transmedics Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Transmedics Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Transmedics Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Transmedics Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Transmedics Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Transmedics Group stock

The Equity of Transmedics Group is 473.10 M USD in 2026.

The Equity of Transmedics Group changed from 228.60 M USD to 473.10 M USD, representing a 106.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Transmedics Group since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Transmedics Group historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Transmedics Group

All Key Metrics — Transmedics Group